Literature DB >> 2652252

The BCG story: lessons from the past and implications for the future.

P E Fine1.   

Abstract

BCG (bacille Calmette-Guérin) vaccines are at once among the least satisfactory and yet the most widely used of all vaccines today. Their variable efficacy against tuberculosis and leprosy is still not understood and points to a fundamental unsolved problem in vaccine immunology. The extensive use of BCG vaccines means that there are few BCG-free populations in the world that would be suitable for trials of future antimycobacterial vaccines. These facts have implications with regard to strategies for the development and testing of new vaccines against mycobacterial diseases.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2652252     DOI: 10.1093/clinids/11.supplement_2.s353

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  58 in total

1.  Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model.

Authors:  M A Horwitz; G Harth; B J Dillon; S Maslesa-Galic'
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

2.  Activation of an interleukin-4 mRNA-producing population of peripheral blood mononuclear cells after infection with Mycobacterium bovis or vaccination with killed, but not live, BCG.

Authors:  S Hook; F Griffin; C Mackintosh; G Buchan
Journal:  Immunology       Date:  1996-06       Impact factor: 7.397

3.  Tracking antigen-specific CD8 T lymphocytes in the lungs of mice vaccinated with the Mtb72F polyprotein.

Authors:  Scott M Irwin; Angelo A Izzo; Steven W Dow; Y A W Skeiky; Steven G Reed; Mark R Alderson; Ian M Orme
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

4.  Listeria-Vectored Vaccine Expressing the Mycobacterium tuberculosis 30-Kilodalton Major Secretory Protein via the Constitutively Active prfA* Regulon Boosts Mycobacterium bovis BCG Efficacy against Tuberculosis.

Authors:  Qingmei Jia; Barbara Jane Dillon; Saša Masleša-Galić; Marcus A Horwitz
Journal:  Infect Immun       Date:  2017-08-18       Impact factor: 3.441

5.  Therapy of regional lymphadenitis following BCG vaccination.

Authors:  A Baki; M Oncü; S Usta; K Yildiz; A Karagüzel
Journal:  Infection       Date:  1991 Nov-Dec       Impact factor: 3.553

6.  Improved sensitivity of diagnosis of tuberculosis in patients in Korea via a cocktail enzyme-linked immunosorbent assay containing the abundantly expressed antigens of the K strain of Mycobacterium tuberculosis.

Authors:  A-Rum Shin; Sung Jae Shin; Kil-Soo Lee; Sun-Ho Eom; Seung-Sub Lee; Byung-Soo Lee; Ji-Sook Lee; Sang Nae Cho; Hwa-Jung Kim
Journal:  Clin Vaccine Immunol       Date:  2008-10-22

Review 7.  BCG immunotherapy for bladder cancer--the effects of substrain differences.

Authors:  Christine Gan; Hugh Mostafid; Muhammad Shamim Khan; David J M Lewis
Journal:  Nat Rev Urol       Date:  2013-09-17       Impact factor: 14.432

8.  Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis.

Authors:  M A Horwitz; B W Lee; B J Dillon; G Harth
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

9.  A species-specific nucleotide sequence of Mycobacterium tuberculosis encodes a protein that exhibits hemolytic activity when expressed in Escherichia coli.

Authors:  S C Leão; C L Rocha; L A Murillo; C A Parra; M E Patarroyo
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

10.  Mycobacterium tuberculosis-Induced Bronchoalveolar Lavage Gene Expression Signature in Latent Tuberculosis Infection Is Dominated by Pleiotropic Effects of CD4+ T Cell-Dependent IFN-γ Production despite the Presence of Polyfunctional T Cells within the Airways.

Authors:  Jessica Jarvela; Michelle Moyer; Patrick Leahy; Tracey Bonfield; David Fletcher; Wambura N Mkono; Htin Aung; David H Canaday; Jean-Eudes Dazard; Richard F Silver
Journal:  J Immunol       Date:  2019-09-20       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.